Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory
Karyopharm Therapeutics società ha sostenuto
Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat patients with cancer and other medical conditions leggi di più
I have only been with Karyopharm for less than 3 months, but I am very happy with my decision to join the team!
La cosa più positiva della cultura e l'ambiente presso la tua azienda?
The excitement associated with the expanded use of XPOVIO.
Che cosa ti rende più felice sul posto di lavoro?
Meeting the needs of the teams that I support. Trying to help them be more efficient.
Other Employee Reviews for Karyopharm Therapeutics
×